Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7856018 | 0.90 | LMNA (0.39) | DNM1ALDH1A1TSHRFDPSHSD17B10 | |
| SCHEMBL1245648 | 0.83 | — | — | |
| SCHEMBL27574896 | 0.82 | DNM1 (0.35) | DNM1ALDH1A1TDP1CA2CA1 | |
| SCHEMBL28136609 | 0.76 | DNM1 (0.38) | DNM1ALDH1A1TDP1CA2CA1 | |
| SCHEMBL8465036 | 0.76 | DNM1 (0.38) | DNM1ALDH1A1TDP1CA2CA1 | |
| SCHEMBL8310868 | 0.74 | DNM1 (0.36) | DNM1ALDH1A1TDP1CA2CA1 | |
| SCHEMBL16969615 | 0.74 | FDPS (0.38) | DNM1ALDH1A1TDP1CA2CA1 | |
| SCHEMBL1961203 | 0.73 | LMNA (0.38) | DNM1ALDH1A1TSHRFDPSLMNA | |
| SCHEMBL28332620 | 0.73 | LMNA (0.38) | DNM1ALDH1A1TSHRFDPSLMNA | |
| SCHEMBL27326152 | 0.73 | LMNA (0.38) | DNM1ALDH1A1TSHRFDPSHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287011-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-14 | — | — | US | disclosed |
| CN-114591294-A | Triazolone compound containing chloropyridine methylene as well as preparation method and application thereof | 中国农业大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-105008331-A | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC | 2015-10-28 | — | — | CN | disclosed |
| US-6906214-B2 | Preparation of aromatic organozinc compounds and composition therefore | RHODIA CHIMIE (FR) | 2005-06-14 | — | — | US | disclosed |
| US-20040254064-A1 | Method for electrolytic heterocoupling between an aryl(pseudo) halide and an ester containing an ethylenic unsaturation, use of cobalt in order to carry out said coupling and composition therefor | RHODIA CHIMIE (FR) | 2004-12-16 | — | — | US | disclosed |
| US-20040236155-A1 | Preparation of aromatic organozinc compounds and composition therefor | SHASUN PHARMA SOLUTIONS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6808655-B1 | ELECTROLYSIS ON AN INERT CATHODE LIQUID MIXTURE OF COBALT SALT, ZINC SALT, AND ORGANIC HALIDE; RECOVERING | RHODIA CHIMIE (FR) | 2004-10-26 | — | — | US | disclosed |
| US-20040186328-A1 | Process of heterocoupling by electrolytic microbattery, use of cobalt for implementing said coupling and composition for doing so | RHODIA CHIMIE (FR) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186328-A1 | Process of heterocoupling by electrolytic microbattery, use of cobalt for implementing said coupling and composition for doing so | HCN2, HCN1, TET2 | DNM1 459/4885ALDH1A1 1250/4885TDP1 3905/4885 |
| US-20230287011-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OXGR1, OCIAD1 | DNM1 4122/4885ALDH1A1 983/4885TDP1 4760/4885 |
| US-20040236155-A1 | Preparation of aromatic organozinc compounds and composition therefor | SLC39A11, SLC39A7, SLC30A7 | DNM1 3887/4885ALDH1A1 2019/4885TDP1 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.